Holen Sie sich die Stockscreener-App
316.62
0.47%
1.6793
Alnylam Pharmaceuticals Inc Aktie (ALNY) Neueste Nachrichten
What makes Alnylam Pharmaceuticals Inc. stock price move sharplyFree Top Growth Stock Recommendations - beatles.ru
SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Investors of an Investigation Involving Possible Securities Fraud Violations by Officers of Alnylam Pharmaceuticals, Inc. (ALNY) - ACCESS Newswire
Gene Therapy Market to Hit US$36.55 Billion by 2032 with 19.4% CAGR | MarketsandMarkets™ - Barchart.com
Alnylam Pharmaceuticals (ALNY) Target Price Raised by Citigroup | ALNY Stock News - GuruFocus
Alnylam (ALNY) Receives Price Target Boost from Citi | ALNY Stoc - GuruFocus
Market Sentiment Around Loss-Making Alnylam Pharmaceuticals, Inc. (NASDAQ:ALNY) - simplywall.st
Analyst Maintains Buy Rating and Raises PT for ALNY | ALNY Stock News - GuruFocus
Alnylam Pharmaceuticals’ SWOT analysis: broad label approval boosts stock outlook - Investing.com
BMO Capital Maintains ‘Outperform’ Rating on Alnylam Pharmaceuticals, Inc. (ALNY); Raises PT - MSN
OXLUMO® (lumasiran injection) Now Reimbursed in Canada For the Treatment of Primary Hyperoxaluria Type 1 (PH1) in Pediatric and Adult Patients - Yahoo Finance
Alnylam's Norton site is 'springboard' for expanding manufacturing capacity - The Business Journals
Alnylam Pharma Beats Inventorship Suit Tied To COVID-19 Jab - Law360
A Glimpse Into The Expert Outlook On Alnylam Pharmaceuticals Through 9 Analysts - Nasdaq
Needham Raises Price Target for Alnylam Pharmaceuticals (ALNY) to $377 | ALNY Stock News - GuruFocus
Growth Stock Portfolio: 12 Companies with At Least 30% Annual Growth Rates - Insider Monkey
Alnylam Stock Plummets 31.67% with 2.10 Billion Shares Traded Ranking 423rd in Volume Amid Legal Victory - AInvest
Alnylam Pharma Appoints New Chief R&D Officer - TipRanks
Alnylam Announces Promotion of Pushkal Garg as Executive Vice President and Chief Research and Development Officer - MarketScreener
Alnylam Promotes Pushkal Garg to Chief Research and Development Officer - citybiz
Alnylam appoints Pushkal Garg as chief research and development officer - Investing.com Australia
Alnylam appoints Pushkal Garg as chief research and development officer By Investing.com - Investing.com Nigeria
Alnylam (ALNY) Names New Chief R&D Officer to Drive Innovation | - GuruFocus
Alnylam Announces Promotion of Pushkal Garg to Chief Research an - GuruFocus
Alnylam Announces Promotion of Pushkal Garg to Chief Research and Development Officer - Business Wire
Alnylam Pharmaceuticals stock hits all-time high at $311.24 By Investing.com - Investing.com Canada
Global RNAi Technology Market: Opportunities in Targeted - openPR.com
Japan’s Isshiki bolsters life sciences practice with senior hire - | Asian Legal Business
Here's How Much You Would Have Made Owning Alnylam Pharmaceuticals Stock In The Last 20 Years - Benzinga
Antisense Oligonucleotides Market is expected to reach US$ - openPR.com
Exploring High Growth Tech Stocks In The US This June 2025 - simplywall.st
Alnylam Pharmaceuticals’ SWOT analysis: stock poised for growth in expanding ATTR-CM market - Investing.com Canada
Acute Intermittent Porphyria Market Predicted to See Upsurge - openPR.com
From Kentucky farm to founding Biogen: New documentary traces life of Phil Sharp - The Business Journals
Where are the Opportunities in (ALNY) - news.stocktradersdaily.com
Primary Hyperoxaluria Pipeline 2025: FDA Updates, Therapy - openPR.com
Healey boosts life sciences tax incentives as 33 companies plan major expansions - The Business Journals
ALNY Stock: JP Morgan Raises Price Target to $338 | ALNY Stock N - GuruFocus
What 18 Analyst Ratings Have To Say About Alnylam Pharmaceuticals - Benzinga
Homozygous Familial Hypercholesterolemia Market to Reach New - openPR.com
Homozygous Familial Hypercholesterolemia Market to Reach New Heights in Growth by 2034, DelveInsight Predicts | Arrowhead Pharma, Novartis, Alnylam Pharma, LIB Therapeutics, Amryt Pharma - The Globe and Mail
JPMorgan Ups Price Target for Alnylam (ALNY) Following Amvuttra Forecast Revision | ALNY Stock News - GuruFocus
Alnylam Wins EC Nod for Label Expansion of Amvuttra for ATTR-CM - MSN
The European Commission Approves Alnylam’s AMVUTTRA - Insider Monkey
John Maraganore joins Axion Bio board to advance cancer therapy By Investing.com - Investing.com Canada
Former Alnylam CEO Who Built $40B Company Backs Instil Bio's Novel Cancer Drug Program - Stock Titan
EC approves Alnylam’s vutrisiran for ATTR-CM treatment - Yahoo Finance
Latest Federal Court Cases: Alnylam Pharmaceuticals, Inc. v. Moderna, Inc. - JD Supra
Dyslipidemia Market to Reach New Heights in Growth by 2034, - openPR.com
Alnylam gets EU approval for Amvuttra in heart disorder treatment - MSN
Alnylam Receives European Commission Approval for AMVUTTRA® (vut - GuruFocus
European Approval Expansion for Alnylam's (ALNY) AMVUTTRA | ALNY Stock News - GuruFocus
Alnylam (ALNY) Secures EU Approval for Amvuttra in Cardiomyopathy - GuruFocus
Transcript : Alnylam Pharmaceuticals, Inc. Presents at Goldman Sachs 46th Annual Global Healthcare Conference 2025, Jun-09-2025 09 - MarketScreener
Alnylam Gets EU Approval for RNAi Drug to Treat Transthyretin Amyloidosis With Cardiomyopathy - MarketScreener
EC approves first RNAi therapy for ATTR cardiomyopathy By Investing.com - Investing.com Nigeria
Alnylam Receives European Commission Approval for AMVUTTRA® (vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy | ALNY Stock News - GuruFocus
(vutrisiran) for the Treatment of ATTR Amyloidosis with Cardiomyopathy - Business Wire
0.60%
1.90%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):